Opendata, web and dolomites

Tuberculini SIGNED

A novel in-vitro diagnostic test for drug-resistant tuberculosis and a personalized antibiotic treatment plan.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Tuberculini project word cloud

Explore the words cloud of the Tuberculini project. It provides you a very rough idea of what is the project "Tuberculini" about.

addressable    positively    amplify    antibiotic    clemedi    patient    therapy    inability    diagnostic    diseases    susceptibility    detection    world    uses    2050    off    proprietary    competitive    commercial    platform    contributor    global    caused    primers    detect    companies    learning    disease    sme    ivd    swiss    matching    feasibility    generation    dna    algorithms    mdr    drug    profiles    dickinson    minimum    mortalities    hours    vs    advice    vitro    antimicrobial    company    annotate    diagnosed    ngs    causes    founded    machine    ag    tb    lifescience    resistant    tuberculosis    vision    significantly    opportunity    73    zurich    followed    university    hain    personalized    financial    48    smei    business    240k    analyze    total    ivds    10k    infectious    infections    market    battle    2019    death    competitors    rapid    data    antibiotics    resistance    valued    prescription    solution    cepheid    advantage    p1    person    diagnose    12    tests    spin    samples    becton    plan    obtaining    larger    tuberculini    sequencing    24   

Project "Tuberculini" data sheet

The following table provides information about the project.

Coordinator
CLEMEDI AG 

Organization address
address: WAGISTRASSE 12
city: SCHLIEREN
postcode: CH-8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CLEMEDI AG CH (SCHLIEREN) coordinator 50˙000.00

Map

 Project objective

Company: Clemedi AG is a Swiss SME, founded in 2019 as a spin-off from the University of Zurich, with the aim to develop in vitro diagnostic (IVD) tests for antibiotic resistance and susceptibility in infectious diseases. The vision of Clemedi is to support the global battle against antibiotic resistance by developing IVDs that will allow personalized prescription of antibiotics.

Need to address: Antimicrobial resistant infections will be among the world’s leading causes of death by 2050. Multi-drug-resistant tuberculosis (MDR-TB) is a large contributor to death by antimicrobial resistance, with over 240k global mortalities (of which 10k in Europe) per year. Many of these are caused by the inability to detect resistance and antibiotic susceptibility in the diagnostic process.

Solution: Clemedi is developing a unique platform to rapidly diagnose drug-resistant infectious diseases, including MDR-TB, and rapidly provide a matching therapy plan. The platform uses proprietary primers to amplify specific DNA from patient samples, followed by next-generation sequencing (NGS) analysis. Machine-learning algorithms are then used to annotate the NGS data, and determine susceptibility or resistance based on DNA-profiles to provide a focused advice on antibiotic therapy, within 24-48 hours after obtaining a patient’s sample.

Business opportunity: The minimum total addressable market for Clemedi (i.e. every person that needs to be diagnosed for MDR-TB) is valued at €73.7 M. Competitors are companies that also develop IVDs for rapid detection of MDR-TB, such as Hain Lifescience, Cepheid and Becton-Dickinson. The main competitive advantage of Tuberculini is its ability to analyze susceptibility for a significantly larger number of antibiotics (12 vs. 1-5). Only this can positively impact disease management.

Feasibility study: Financial support from the SMEi P1 will be used to assess the technical and commercial feasibility of Tuberculini, Clemedi’s IVD for MDR-TB.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TUBERCULINI" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TUBERCULINI" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DNA DS (2019)

DNA Data storage

Read More  

ERGOVIAkinematix (2018)

New wearable measurement devices for Industry 4.0 based on gaming motion-capture system

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More